1. Home
  2. APRE vs KUKE Comparison

APRE vs KUKE Comparison

Compare APRE & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APRE
  • KUKE
  • Stock Information
  • Founded
  • APRE 2006
  • KUKE 2002
  • Country
  • APRE United States
  • KUKE China
  • Employees
  • APRE N/A
  • KUKE N/A
  • Industry
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • KUKE Other Consumer Services
  • Sector
  • APRE Health Care
  • KUKE Real Estate
  • Exchange
  • APRE Nasdaq
  • KUKE Nasdaq
  • Market Cap
  • APRE 21.2M
  • KUKE 18.9M
  • IPO Year
  • APRE 2019
  • KUKE 2021
  • Fundamental
  • Price
  • APRE $2.62
  • KUKE $0.31
  • Analyst Decision
  • APRE Strong Buy
  • KUKE
  • Analyst Count
  • APRE 2
  • KUKE 0
  • Target Price
  • APRE $15.50
  • KUKE N/A
  • AVG Volume (30 Days)
  • APRE 35.9K
  • KUKE 126.0K
  • Earning Date
  • APRE 03-25-2025
  • KUKE 04-15-2025
  • Dividend Yield
  • APRE N/A
  • KUKE N/A
  • EPS Growth
  • APRE N/A
  • KUKE N/A
  • EPS
  • APRE N/A
  • KUKE N/A
  • Revenue
  • APRE $1,310,839.00
  • KUKE $14,784,158.00
  • Revenue This Year
  • APRE $134.21
  • KUKE N/A
  • Revenue Next Year
  • APRE N/A
  • KUKE N/A
  • P/E Ratio
  • APRE N/A
  • KUKE N/A
  • Revenue Growth
  • APRE 130.31
  • KUKE 10.48
  • 52 Week Low
  • APRE $2.15
  • KUKE $0.23
  • 52 Week High
  • APRE $8.85
  • KUKE $4.07
  • Technical
  • Relative Strength Index (RSI)
  • APRE 30.05
  • KUKE 34.52
  • Support Level
  • APRE $2.59
  • KUKE $0.36
  • Resistance Level
  • APRE $3.72
  • KUKE $0.50
  • Average True Range (ATR)
  • APRE 0.35
  • KUKE 0.06
  • MACD
  • APRE -0.13
  • KUKE -0.01
  • Stochastic Oscillator
  • APRE 1.41
  • KUKE 4.92

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

About KUKE Kuke Music Holding Limited

Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.

Share on Social Networks: